Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announced today its schedule for the publication of financial information for 2015.

Event   Dates* 2014 Full-Year Sales   January 7, 2015 2014 Full-Year Results   March 31, 2015 2015 First-Quarter Sales   April 28, 2015 Annual General Meeting   June 17, 2015 2015 First-Half Sales   July 28, 2015 2015 First-Half Results   September 15, 2015 2015 Third-Quarter Sales   October 27, 2015

Note (*): Press releases are published after market closes. Subject to modification.

About IMPLANET

Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2013 sales of €6.7 million. For further information, please visit www.implanet.com.

IMPLANET is listed on Compartment C of Euronext™ Paris.Ticker: IMPL - ISIN code: FR0010458729

IMPLANETLudovic Lastennet, Tel.: +33 (0)5 57 99 55 55CEOinvestors@implanet.comorNewCapInvestor RelationsFlorent Alba, Tel.: +33 (0)1 44 71 94 94implanet@newcap.frorNewCapPress RelationsNicolas Merigeau, Tel.: +33 (0)1 44 71 94 98implanet@newcap.fr